Cannabidiolic acid

Get a Price/Quote

MOQ : 1 Kilograms

Cannabidiolic acid Specification

Usage
Cannabidiolic acid inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells, apparently through a mechanism involving inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA.

Purity
97%

Molecular Weight
358.5 Grams (g)

Melting Point
66 °C (151 °F)

Molecular Formula
C22H30O4

Cannabidiolic acid Trade Information

Minimum Order Quantity
1 Kilograms

Payment Terms
Cash in Advance (CID), Cash Advance (CA)

Supply Ability
500 Kilograms Per Month

Delivery Time
3-4 Week

Sample Available
Yes

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Main Export Market(s)
Western Europe, Australia, Eastern Europe, Central America, Africa, Middle East, South America, Asia, North America

Main Domestic Market
All India

About Cannabidiolic acid

Cannabidiolic acidSynonym: CBDA CAS Number 1244-58-2 Empirical Formula (Hill Notation) C22H30O4 Molecular Weight 358.47 grade analytical standard assay 95% (HPLC) form neat shelf life limited shelf life, expiry date on the label drug control USDEA Schedule I; Home Office Schedule 1; regulated under CDSA - not available from Sigma-Aldrich Canada application(s) HPLC: suitable gas chromatography (GC): suitable

FAQs of Cannabidiolic acid:

Q: What is the purity level of Cannabidiolic acid?

A: The purity level of Cannabidiolic acid is 97%.

Q: What is the molecular formula of Cannabidiolic acid?

A: The molecular formula of Cannabidiolic acid is C22H30O4.

Q: What is the melting point of Cannabidiolic acid?

A: The melting point of Cannabidiolic acid is 66 C (151 F).

Q: What is the molecular weight of Cannabidiolic acid?

A: The molecular weight of Cannabidiolic acid is 358.5 grams (g).

Q: What is the usage of Cannabidiolic acid in inhibiting human breast cancer cell migration?

A: Cannabidiolic acid inhibits migration of the highly invasive MDA-MB-231 human breast cancer cells. This inhibition occurs through a mechanism involving the inhibition of cAMP-dependent protein kinase A, coupled with an activation of the small GTPase, RhoA.

Tell us about your requirement